Chronic Kidney Disease After Orthotopic Liver Transplantation: Impact of Hepatitis C Infection

2011 ◽  
Vol 91 (11) ◽  
pp. 1245-1249 ◽  
Author(s):  
Ranjeeta Bahirwani ◽  
Oren Shaked ◽  
Shanu Kurd ◽  
Roy Bloom ◽  
K. Rajender Reddy
2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Fabrizio Fabrizi ◽  
Piergiorgio Messa ◽  
Paul Martin

The 2011 report of the World Health Organization General Assembly on noncommunicable diseases identified chronic kidney disease as a worldwide health issue posing a heavy economic burden. Hepatitis C virus infection, which is responsible for over 1 million deaths resulting from cirrhosis and liver cancer, is linked to chronic kidney disease in several ways; some forms of renal disease are precipitated by hepatitis C and patients with end-stage chronic renal disease are at increased risk for acquiring HCV. The aim of this review is to update the evidence on the relationship between hepatitis C infection and chronic kidney disease. Information has been accumulated in the last decade indicating that HCV plays an adverse effect on the incidence and progression of chronic kidney disease; a novel meta-analysis of observational studies (seven longitudinal studies; 890,560 unique individuals) found a relationship between hepatitis C seropositivity and incidence of reduced estimated glomerular filtration rate (adjusted relative risk, 1.70; 95% CI, 1.20; 2.39; P=0.002) in the adult general population. In addition to conventional risk factors, hepatitis C may be an additional factor for the development of chronic kidney disease, and an atheromasic activity of hepatitis C virus has been mentioned. The link between hepatitis C and atherosclerosis could also explain the excess risk of cardiovascular mortality that has been observed among hepatitis C virus seropositive patients undergoing maintenance dialysis. A number of biologically plausible mechanisms related to hepatitis C virus have been hypothesized to contribute to atherosclerosis. Implementation of effective treatment intervention towards hepatitis C is required to decrease the healthcare burden of hepatitis C and to prevent the progression of chronic renal disease.


2016 ◽  
Vol 3 (suppl_1) ◽  
Author(s):  
Carla V. Rodriguez ◽  
Jean Marie Arduino ◽  
Jin-Wen Hsu ◽  
Rong Wei ◽  
Kevin Rubenstein ◽  
...  

2016 ◽  
Vol 3 (suppl_1) ◽  
Author(s):  
Sara Tartof ◽  
Jean Marie Arduino ◽  
Rong Wei ◽  
Jin-Wen Hsu ◽  
Kevin Rubenstein ◽  
...  

2020 ◽  
Vol 24 (9) ◽  
pp. 806-812
Author(s):  
Jiang-Chen Peng ◽  
Yu- Jie Li ◽  
Jie -Min Wang ◽  
Ming-Li Zhu ◽  
Yuan Gao

2002 ◽  
Vol 122 (4) ◽  
pp. 889-896 ◽  
Author(s):  
Lisa M. Forman ◽  
James D. Lewis ◽  
Jesse A. Berlin ◽  
Harold I. Feldman ◽  
Michael R. Lucey

2008 ◽  
Vol 86 (Supplement) ◽  
pp. 653
Author(s):  
J Frazier ◽  
G Lipka ◽  
D W. Johnson ◽  
C Hawley ◽  
S Campbell ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document